Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-21

Clinical Trial Update: Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the efficacy and tolerability of rimegepant for acute treatment of migraine in adults unsuitable for triptans.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NURTEC ODT (RIMEGEPANT SULFATE)

Snippet

Sponsor: Pfizer | Conditions: Migraine | Phase 4 | Status: COMPLETED | Results posted: 2026-04-21